on Juno Biomedical, Inc.
CELLTech™ DBS: Harnessing AI for Brain Tissue Healing
Juno Biomedical, Inc. has announced its flagship deep brain stimulation (DBS) device, CELLTech™ DBS, which aims to optimize brain tissue healing post-damage. The device integrates artificial intelligence and deep brain monitoring to offer personalized treatment options. According to Chief Scientific Officer Trisha Pfluger, CELLTech™ DBS is both scalable and cost-effective to manufacture.
Currently developed in the U.S., CELLTech™ DBS is part of the FDA's Early Feasibility Study (EFS) Program. CEO Nicholas Totagrande highlights the extensive collaboration with the FDA, emphasizing the resolve of design, protocol, and safety regulations to pave the way for upcoming clinical trials.
The device is designed to treat brain tissue damage from strokes and potentially other disorders. Pfluger notes that the therapy employs AI to refine treatments at an individual level by capturing the correlation between brain repair and brain activity.
Totagrande believes CELLTech™ DBS can improve the quality of life for those suffering brain function loss, making advanced treatments accessible to more patients.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Juno Biomedical, Inc. news